AUS
NZ
UK
CA
USA
IND
Highlights
- Filamon’s ALPHA-003 drug discovery offers a more efficient approach to the treatment of dementia.
- Unlike current dementia treatments that focus on minimising damage after it has already happened, ALPHA-003 aims to protect brain cells from neuroinflammation and preserve microtubule integrity.
- ALPHA-003 is currently undergoing pre-clinical testing with plans to enter clinical trials in 2026.
Filamon Limited, a clinical-stage Australian biotechnology company, is making strides in developing anti-inflammatory drugs for age-related chronic degenerative diseases. The company has recently announced a groundbreaking drug discovery it believes could transform the treatment of dementia.
According to the World Health Organization, dementia is a syndrome caused by various diseases that gradually destroys nerve cells and damages the brain. This leads to a decline in cognitive function beyond what is typical with normal aging.
Current dementia treatments largely aim to minimise damage after significant brain cell deterioration have occurred. In response, Filamon has developed “ALPHA-003”, an innovative drug designed to prevent such damage by preserving the integrity of brain cell microtubules and shielding them from the destructive effects of neuroinflammation.
Highlighting the development, Associate Professor Kieran Scott, Professor of Oncology at Western Sydney University, and co-discoverer of ALPHA-003, said, “To date, no one has found a way of preventing microtubular destruction. We believe ALPHA-003 has the potential to be that first drug by stabilising the two main brain cell components whose job is to protect microtubules from damage – tau and neurofilaments.”
Filamon has also confirmed that the drug can successfully cross the mammalian blood-brain barrier.
In addition to ALPHA-003, Filamon’s pipeline includes several promising programs aimed at addressing age-related diseases.
The financial and emotional burden of dementia care, along with the strain on national health budgets, makes Filamon’s work increasingly significant. The company aims to offer the aging population a renewed opportunity for independent, productive living through innovative research and treatments.
